Peptides for Weight Loss: AOD-9604, CJC-1295/Ipamorelin, 5-Amino-1MQ, and More

Medically reviewed by Truventa Medical physicians | Updated April 2026

Peptides have become one of the most talked-about tools in the evolving landscape of medical weight management and body composition optimization. While they lack the widespread recognition of GLP-1 medications like semaglutide, a growing number of patients — particularly those focused on fat loss alongside muscle preservation — are exploring peptide-based approaches under physician supervision.

In this guide, we'll examine the most commonly discussed peptides used for weight and fat loss goals, how they work, what the evidence says, and how they fit into a comprehensive body composition strategy.

What Are Peptides?

Peptides are short chains of amino acids — the building blocks of proteins. Naturally occurring peptides act as signaling molecules throughout the body, regulating everything from hormone release to immune function to tissue repair. Therapeutic peptides are either derived from or designed to mimic these natural signaling molecules.

Unlike traditional pharmaceuticals that often work through receptor blockade or enzyme inhibition, many peptides work by stimulating or modulating natural biological processes — in some cases, essentially telling the body to do more of what it already does, but more effectively.

Explore Truventa Medical's peptide therapy options to learn what may be available for your goals.

AOD-9604: The "Fat Fragment"

What Is AOD-9604?

AOD-9604 (Anti-Obesity Drug 9604) is a modified fragment of human growth hormone — specifically, it represents the C-terminal fragment of the growth hormone molecule (amino acids 176–191). Researchers developed AOD-9604 in the hope of capturing the fat metabolism properties of growth hormone while eliminating the effects on blood sugar and insulin-like growth factor (IGF-1) that make full growth hormone less suitable as a weight loss agent.

How AOD-9604 May Work

Studies suggest AOD-9604 may:

• Stimulate lipolysis (the breakdown of fat stored in fat cells)
• Inhibit lipogenesis (the formation and storage of new fat)
• Mimic the fat-metabolizing effects of growth hormone without significantly affecting blood glucose or IGF-1 levels

Evidence and Status

AOD-9604 was studied in human clinical trials for obesity treatment in the early 2000s. While early Phase II trials showed some promising signals for fat reduction, Phase III trials were not completed, and the compound did not receive FDA approval as an anti-obesity drug. It holds FDA GRAS (Generally Recognized As Safe) status for use in food, which is sometimes cited in marketing materials — though this is a different standard than drug approval.

AOD-9604 is currently available as a compounded peptide through licensed physicians. It is typically administered via subcutaneous injection. The clinical evidence base is smaller than for approved medications, and patients should have realistic expectations and work closely with a physician who can track progress and adjust accordingly.

CJC-1295 and Ipamorelin: Growth Hormone Optimization for Body Composition

What Are CJC-1295 and Ipamorelin?

CJC-1295 and Ipamorelin are almost always used together and are among the most popular peptides in the body composition space. Understanding each:

• CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to release growth hormone and has an extended half-life compared to natural GHRH, meaning more sustained stimulation.
• Ipamorelin is a growth hormone secretagogue — it stimulates growth hormone release through a separate pathway (the ghrelin receptor) and is known for producing a "clean" GH pulse with minimal effect on other hormones like cortisol or prolactin.

Together, they work synergistically to produce a more robust and sustained release of growth hormone than either would alone.

How CJC-1295/Ipamorelin May Support Fat Loss

Growth hormone plays a central role in body composition. It promotes:

• Lipolysis: GH directly stimulates the release of fatty acids from fat tissue for use as fuel
• Muscle protein synthesis: Indirectly through IGF-1 production, GH supports muscle growth and maintenance
• Improved recovery: Better sleep quality (GH is released primarily during deep sleep) and faster recovery from exercise

Many patients using CJC-1295/Ipamorelin report improved body composition over several months — specifically, a gradual shift toward less fat mass and more lean muscle — even without dramatic changes in weight on the scale. This makes it particularly useful for patients who want to look and feel leaner while preserving muscle during a calorie deficit.

Typical Protocol

CJC-1295/Ipamorelin is typically administered via subcutaneous injection before bed (to align with the body's natural GH pulsatility during sleep). Some protocols also include a morning injection. Results typically develop over 3–6 months of consistent use.

5-Amino-1MQ: A Newer Player in Fat Metabolism

What Is 5-Amino-1MQ?

5-Amino-1MQ is a small molecule compound (technically a methylquinolinium compound rather than a traditional peptide, though it is often grouped with peptide therapies) that works as an inhibitor of an enzyme called NNMT (nicotinamide N-methyltransferase).

The NNMT Connection

NNMT is an enzyme found primarily in fat tissue that plays a role in regulating fat cell metabolism. When NNMT is overactive — as it tends to be in obesity and metabolic disease — it promotes a state in which fat cells are more efficient at storing energy and less responsive to lipolysis signals.

Studies suggest that inhibiting NNMT with compounds like 5-Amino-1MQ may:

• Reduce fat cell size and fat mass
• Increase cellular energy expenditure within fat tissue
• Improve insulin sensitivity
• Potentially counteract some of the metabolic adaptations that make it hard to lose weight

The research on 5-Amino-1MQ is still early-stage, primarily from animal studies, with human data limited. It is available as a compounded oral capsule. Patients interested in this compound should understand the current evidence limitations and discuss them with a knowledgeable physician.

Semaglutide vs. Peptides for Fat Loss: How to Think About It

If you're comparing peptides to GLP-1 medications for weight loss, it helps to think of them as tools that work through fundamentally different mechanisms:

Factor	GLP-1 Medications (Semaglutide/Tirzepatide)	Body Composition Peptides (CJC-1295/Ipamorelin, AOD-9604)
Primary mechanism	Appetite suppression, slowed gastric emptying	GH stimulation, direct fat metabolism effects
Weight loss magnitude	15–25% of body weight (clinical trials)	Modest (varies, often 5–10 lbs fat loss over months)
Muscle preservation	Some concern about muscle loss during rapid weight loss	May actively support muscle preservation and gain
Best for	Significant weight reduction, metabolic disease	Body recomposition, preserving lean mass, adjunct support
FDA approval status	FDA-approved for obesity/diabetes	Not FDA-approved (compounded)

Combining Peptides with Other Approaches

One of the areas where peptides may offer the most value is as part of a combined strategy:

• GLP-1 + CJC-1295/Ipamorelin: Using a GLP-1 medication to achieve primary weight loss while adding CJC-1295/Ipamorelin to support growth hormone levels and help preserve lean muscle during caloric restriction. Muscle preservation is a significant concern during rapid weight loss on GLP-1 medications.
• Peptides + resistance training: Peptides for body composition work best when combined with a consistent resistance training program and adequate protein intake.
• Peptides + metabolic optimization: Some patients combine peptides with other interventions like testosterone optimization (for men with low T) or thyroid management to address multiple factors influencing body composition simultaneously.

Any combination approach should be supervised by a licensed physician who can monitor for interactions and adjust protocols based on response. Explore our full peptide therapy page for more details on available options.

What to Expect: Realistic Outcomes from Peptide Therapy

It's important to have realistic expectations when starting peptide therapy for body composition goals:

• Peptides like CJC-1295/Ipamorelin typically work gradually over 3–6 months — they are not rapid weight loss agents
• Results are most apparent in body composition changes (less fat, more lean mass) rather than rapid scale weight loss
• Consistent protocol adherence, adequate protein intake, and resistance training significantly amplify results
• Some patients report improved sleep, recovery, and energy as early benefits, with body composition changes following

If your primary goal is significant weight reduction (e.g., losing 30+ pounds), GLP-1 medications are likely to be a more central part of your treatment plan, with peptides potentially serving as a complementary element.

Frequently Asked Questions

What peptides are used for weight loss?

Several peptides are used in the context of weight management and body composition improvement. Commonly discussed options include AOD-9604 (a fragment of growth hormone thought to influence fat metabolism), CJC-1295 and Ipamorelin (growth hormone-releasing peptides that may increase lean mass and support fat loss), and 5-Amino-1MQ (which targets an enzyme involved in fat cell metabolism). These are typically compounded peptides prescribed by physicians and not FDA-approved as weight loss drugs.

How do peptides compare to semaglutide or tirzepatide for weight loss?

GLP-1 medications like semaglutide and tirzepatide generally produce more significant weight loss (15–25% of body weight in clinical trials) compared to peptides like AOD-9604 or CJC-1295/Ipamorelin. Peptides are often considered complementary tools — particularly for optimizing body composition (preserving or building muscle while reducing fat) — rather than primary weight loss treatments.

Is AOD-9604 FDA-approved?

AOD-9604 is not FDA-approved as a drug for any indication. It is available as a compounded peptide through licensed physicians and compounding pharmacies. Patients considering AOD-9604 should work with a licensed physician who can evaluate appropriateness, discuss the current evidence, and monitor for any adverse effects.

What is CJC-1295/Ipamorelin and how does it help with fat loss?

CJC-1295 is a growth hormone-releasing hormone (GHRH) analog, and Ipamorelin is a growth hormone secretagogue. Together, they stimulate the pituitary gland to release more growth hormone. Elevated growth hormone levels support increased muscle protein synthesis, improved fat metabolism (lipolysis), and better recovery from exercise. The body composition changes — more lean mass, less fat — are a byproduct of optimized growth hormone levels.

Can peptides be combined with GLP-1 medications?

Some physicians do use combination approaches — for example, using a GLP-1 medication for appetite suppression and overall weight loss while using peptides like CJC-1295/Ipamorelin to preserve or build lean muscle mass during the weight loss process. Combining approaches should always be done under physician supervision with appropriate monitoring.

How are weight loss peptides administered?

Most weight loss peptides are administered via subcutaneous injection (small needle under the skin), typically daily or several times per week. Some peptides are available in oral or nasal spray forms, though these routes have reduced bioavailability compared to injections. Your physician will guide you on proper injection technique and dosing schedules.